TLR4 and ovarian carcinoma: Of note, in a transplantation-based ovarian cancer mouse model (i.e., ID8 model), TLR4 agonist LPS was tested to determine whether activation of TLR4 signaling could reshape the cancer immune signature [181]; even though this treatment did not result in survival benefit, it should be pointed out that the ID8 model originated from OSE cells (rather than FTE cells) [182], which do not express TLR pathway-related genes [75].